Lucid Group

What Lucid Group does

Lucid Group is a London-headquartered strategic healthcare communications and consulting firm founded in 2007 by Dennis O'Brien, serving life sciences organisations across the full asset lifecycle—from early development through launch and beyond. The company targets pharmaceutical manufacturers (including top 10 global pharma and ambitious biotech), medical device and consumer health companies, and specialty therapy-area teams in oncology, rare diseases, respiratory, neurology, and medtech. It operates four UK locations (London registered office at Sea Containers House, a second London entity office, plus Macclesfield and Manchester) and one US location in Philadelphia, with a workforce of approximately 400-600 specialists. Lucid is privately held with strategic financial backing from Intermediate Capital Group (ICG), which has supported an acquisition-led growth strategy beginning with the January 2023 acquisition of Synetic Life Sciences.

The company delivers services through five integrated capabilities: Strategy Consulting, Scientific and Medical Communications, Commercial Communications, Lucid Connected Intelligence (a proprietary data platform mining patient healthcare interaction data including diagnosis, prescription, procedure, demographic, and geographic dimensions), and AI-Powered Solutions. It has also productised proprietary tools including Influence Amplifier™ and Impact Validator™ (unveiled at the Medical Affairs Professional Society conference) and operates DiD Agency as a healthcare creative sub-brand. The revenue model is primarily bespoke professional services (consulting and communications engagements) supplemented by data-monetisation analytics using the LCI platform; pricing is not publicly disclosed.

Go-to-market is direct enterprise sales to life sciences organisations through senior relationship management and bespoke team deployment. Documented outcomes include +17% NBRx growth and +50% sales uplift for an asthma brand, 63% oncologist brand recognition within 6 months and 168% of sales target for an oncology launch, 100% state coverage and +106% prescription growth for a branded naloxone launch, and 9X qualified audience volume with a 5.6:1 ROI for a MAVENCLAD omnichannel campaign. Recent strategic moves include US market launch (March 2025), appointment of former Pfizer EVP Rod MacKenzie as Board Chair, and accreditation milestones including ISO 27001 certification (2025), EcoVadis Silver Award (top 25% of over 100,000 rated organisations), and UN Global Compact membership.

Name

Lucid Group

Legal name

Lucid Group, Inc.

Website

https://wearelucidgroup.com

Company type

Public

Founded year

2007

Operating status

Operating

Headcount range

51–100 employees

Short description

Lucid Group is a London-headquartered strategic healthcare communications and consulting firm serving pharmaceutical, biotech, and medical device clients across the asset lifecycle through five integrated capabilities including proprietary data analytics and AI tools.

Ownership category

akta.pro rank

Product category

Healthcare Communications

NAICS

Public Relations Agencies (541820), Advertising, Public Relations, and Related Services (5418), Other Management Consulting Services (541618)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Healthcare & Life Sciences PR (MPAAADAD)

akta.pro secondary industry

Healthcare & Life Sciences PR (BPAFADAJ)

Keywords

• Healthcare communications
• Medical affairs consulting
• Pharmaceutical marketing services
• Scientific communications agency
• Life sciences consulting

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Strategic Consulting Services: Bespoke consulting engagements for life sciences organizations spanning clinical development, medical affairs, asset commercialisation, and HCP/patient engagement
2. Scientific and Medical Communications: Strategic communications services translating scientific insight into impactful narratives supporting global and US markets
3. Commercial Communications: Marketing and promotional communications services for healthcare brands including omnichannel programs and creative development
4. Data-Driven Analytics Services: Analytics services leveraging Lucid Connected Intelligence platform for hyper-targeted media, advanced analytics, and data overlays

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Lucid Group is a global strategic healthcare communications agency that helps life sciences organizations translate scientific evidence into stakeholder belief and market momentum. It delivers bespoke teams across Strategy Consulting, Scientific and Medical Communications, Commercial Communications, and data-driven analytics (Lucid Connected Intelligence), augmented by AI-powered capabilities, to support clients across the full asset lifecycle from clinical development through launch and beyond.

Product overview

Lucid Group is a global strategic healthcare communications agency that operates as a unified platform offering five core integrated capabilities: Strategy Consulting, Scientific and Medical Communications, Commercial Communications, Lucid Connected Intelligence, and AI-Powered Solutions. The company deploys bespoke teams across these capabilities to deliver meaningful impact for clients throughout the asset lifecycle—from early development through launch and beyond. The portfolio includes the DiD Agency sub-brand for creative services. The organization combines scientific rigour, strategic foresight, behavioural insight, commercial ingenuity, and creative storytelling, with AI woven in by design to amplify insight and accelerate execution.

Differentiator

Problem solved

Functional benefit

Products and services

• Strategy Consulting Strategic solutions for life sciences clients combining industry understanding, external healthcare ecosystem expertise, and data- and science-based approaches to set direction and transform ideas into action across the asset lifecycle.
• Scientific and Medical Communications Strategic, problem-solving partner service with deep scientific and therapy-area expertise supporting Global and US markets, translating scientific insight into impactful strategies and compelling narratives for medical affairs and clinical development stakeholders.
• Commercial Communications Healthcare communications service translating evidence into action, belief into momentum, and complexity into clarity through creative storytelling with purpose, supporting commercial teams across launch and brand growth.
• Lucid Connected Intelligence Proprietary business intelligence engine and analytics service that mines patient healthcare interaction data points including diagnosis, prescription, procedure, demographic, and geographic data to define, validate, or uncover new areas of unmet need or behavior for targeting and segmentation.
• AI-Powered Solutions AI-enabled service offering woven into delivery by design, combining human insight, therapeutic depth, and behavior change expertise to amplify insight, accelerate execution, and drive measurable, market-moving results for clients.
• DiD Agency Creative agency sub-brand specializing in healthcare marketing communications, combining data-driven intelligence and strategic creative storytelling to help brands break through and deliver value to healthcare professionals and patients.

Quantifiable outcome

• +17% growth in NBRx share vs prior year for asthma brand
• +10 more outcomes

Named customers9 records

Segments7 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Synetic Life SciencescoreStrategic or Co-development Partner · 18 January 2023Management consulting firm dedicated to life sciences industry, acquired by Lucid Group in January 2023. Provides operating model design and implementation, strategic process and capability building, and portfolio planning support. Combined capabilities create end-to-end partnership across development and commercialisation journey.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Havas Health & You: Global healthcare communications network combining creative, medical, and digital capabilities for pharma and biotech. Directly comparable to Lucid in offering strategy, scientific communications, and omnichannel HCP/patient engagement at enterprise scale.
• Ogilvy Health: Healthcare communications arm of Ogilvy providing advertising, medical education, and brand strategy for pharma. Overlaps with Lucid's commercial communications and creative storytelling capabilities.
• GCI Health: Specialist healthcare public relations agency focused on pharma, biotech, and health tech. Comparable to Lucid in delivering strategic PR and stakeholder communications for top-tier pharma clients.
• Real Chemistry: Healthcare marketing and data-driven communications agency combining creative, PR, and analytics. Comparable to Lucid in serving top pharma with integrated scientific, commercial, and data-led communications engagements.
• ZS Associates: Global consulting and analytics firm with a substantial life sciences practice covering commercial strategy, launch, and real-world evidence. Comparable to Lucid's strategy consulting and Lucid Connected Intelligence analytics offerings.
• Inizio: Healthcare-focused commercialization partner formed from the combination of Ashfield and Huntsworth, providing medical affairs, communications, and consulting across the asset lifecycle. Closely overlaps Lucid's strategy consulting and medical communications offerings.
• Syneos Health Communications: Biopharma solutions provider with a communications arm covering medical affairs, advertising, and patient engagement. Overlaps directly with Lucid's launch-excellence, medical communications, and omnichannel commercial work.
• EVERSANA: Commercial services platform for life sciences spanning patient services, data and analytics, and marketing. Comparable to Lucid in serving enterprise pharma with launch, commercialisation, and data-driven engagement support.

Broad incumbents

• McKinsey & Company (Pharma Practice): Global management consultancy with a leading pharmaceuticals and medical products practice. Overlaps with Lucid at the high end of pharma strategy and launch transformation work, but at a far broader scale and with different delivery economics.
• Deloitte (Life Sciences practice): Big Four advisory with a large life sciences consulting practice spanning R&D, commercial, and technology transformation. Comparable to Lucid's strategy consulting arm but typically operating at enterprise-wide transformation scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/lucid
• Xx.com/mededlucid

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lucid Group